Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 5, 2009, Pages 361-369

  Hollebecque, A ^a   Decaens, T ^b   Boleslawski, E ^a   Mathurin, P ^a   Duvoux, C ^b   Pruvot, F R ^a   Dharancy, S ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; CORTICOSTEROID; DOXORUBICIN; FLUOROURACIL; LICARTIN; MITOMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SORAFENIB; UNCLASSIFIED DRUG;

CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; SHORT SURVEY;

ALGORITHMS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS;

EID: 67349138658     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.02.036     Document Type: Short Survey

References (80)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Bouvier A.M., Remontet L., Jougla E., Launoy G., Grosclaude P., Buemi A., et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 28 (2004) 877-881
3. Befeler A.S., Hayashi P.H., and Di Bisceglie A.M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 128 (2005) 1752-1764
4. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
5. Llovet J.M., and Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 Suppl. 1 (2008) S20-S37
6. Iwatsuki S., Starzl T.E., Sheahan D.G., Yokoyama I., Demetris A.J., Todo S., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214 (1991) 221-228 discussion 228-9
7. Ringe B., Pichlmayr R., Wittekind C., and Tusch G. Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients. World J Surg 15 (1991) 270-285
8. Bismuth H., Chiche L., Adam R., Castaing D., Diamond T., and Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218 (1993) 145-151
9. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
10. Decaens T., Roudot-Thoraval F., Hadni-Bresson S., Meyer C., Gugenheim J., Durand F., et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 12 (2006) 1761-1769
11. Yao F.Y., Ferrell L., Bass N.M., Watson J.J., Bacchetti P., Venook A., et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 33 (2001) 1394-1403
12. Marsh J.W., Casavilla A., Iwatsuki S., Dvorchik I., Subotin M., Balan V., et al. Predicting the risk of tumor recurrence following transplantation for hepatocellular carcinoma. Hepatology 26 (1997) 1689-1691
13. Regalia E., Fassati L.R., Valente U., Pulvirenti A., Damilano I., Dardano G., et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 5 (1998) 29-34
14. Roayaie S., Schwartz J.D., Sung M.W., Emre S.H., Miller C.M., Gondolesi G.E., et al. Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl 10 (2004) 534-540
15. Schlitt H.J., Neipp M., Weimann A., Oldhafer K.J., Schmoll E., Boeker K., et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 17 (1999) 324-331
16. Schreibman I.R., Bejarano P., Martinez E.J., and Regev A. Very late recurrence of hepatocellular carcinoma after liver transplantation: Case report and literature review. Transplant Proc 38 (2006) 3140-3143
17. Dharancy S., Hollebecque A., Boleslawski E., Declerck N., Canva V., Mathurin P., et al. Natural History of recurrent hepatocellular carcinoma after liver transplantation (abstract). Liver Transpl 14 S1 (2008) S129
18. Kim Y.S., Lim H.K., Rhim H., Lee W.J., Joh J.W., and Park C.K. Recurrence of hepatocellular carcinoma after liver transplantation: Patterns and prognostic factors based on clinical and radiologic features. AJR Am J Roentgenol 189 (2007) 352-358
19. Decaens T., Roudot-Thoraval F., Bresson-Hadni S., Meyer C., Gugenheim J., Durand F., et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World J Gastroenterol 12 (2006) 7319-7325
20. Lohe F., Angele M.K., Rentsch M., Graeb C., Gerbes A., Lohrs U., et al. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: Implications for patient selection in liver transplantation. Clin Transplant 21 (2007) 696-701
21. Todo S., and Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: Experience in Japan. Ann Surg 240 (2004) 451-459 discussion 459-61
22. Jonas S., Bechstein W.O., Steinmuller T., Herrmann M., Radke C., Berg T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33 (2001) 1080-1086
23. Tamura S., Kato T., Berho M., Misiakos E.P., O'Brien C., Reddy K.R., et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 136 (2001) 25-30 discussion 31
24. Zavaglia C., De Carlis L., Alberti A.B., Minola E., Belli L.S., Slim A.O., et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 100 (2005) 2708-2716
25. Dumortier J., Lombard-Bohas C., Valette P.J., Boillot O., Scoazec J.Y., Berger F., et al. Needle tract recurrence of hepatocellular carcinoma after liver transplantation. Gut 47 (2000) 301
26. Durand F., Regimbeau J.M., Belghiti J., Sauvanet A., Vilgrain V., Terris B., et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 35 (2001) 254-258
27. Fiore F., Daniele B., De Maio E., Tambaro R., Iaffaioli V.R., Barbarisi A., et al. Subcutaneous seeding of hepatocellular carcinoma after fine-needle percutaneous biopsy. J Clin Gastroenterol 33 (2001) 171
28. Ng K.K., Poon R.T., Lo C.M., Liu C.L., Lam C.M., Ng I.O., et al. Impact of preoperative fine-needle aspiration cytologic examination on clinical outcome in patients with hepatocellular carcinoma in a tertiary referral center. Arch Surg 139 (2004) 193-200
29. Schotman S.N., De Man R.A., Stoker J., Zondervan P.E., and Ijzermans J.N. Subcutaneous seeding of hepatocellular carcinoma after percutaneous needle biopsy. Gut 45 (1999) 626-627
30. Sood A., Midha V., and Sood N. Needle track metastasis of primary liver carcinoma after percutaneous needle aspiration. Am J Gastroenterol 97 (2002) 765-766
31. Cillo U., Vitale A., Bassanello M., Boccagni P., Brolese A., Zanus G., et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 239 (2004) 150-159
32. Sotiropoulos G.C., Malago M., Molmenti E., Paul A., Nadalin S., Brokalaki E., et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: Is clinical tumor classification before transplantation realistic?. Transplantation 79 (2005) 483-487
33. Reddy M.S., and Manas D.M. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 83 (2007) 367-368
34. Roberts J.P. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 11 Suppl. 2 (2005) S45-S46
35. Shah S.A., Tan J.C., McGilvray I.D., Cattral M.S., Cleary S.P., Levy G.A., et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 81 (2006) 1633-1639
36. Yao F.Y., Kinkhabwala M., LaBerge J.M., Bass N.M., Brown Jr. R., Kerlan R., et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 5 (2005) 795-804
37. Adler M., De Pauw F., Vereerstraeten P., Fancello A., Lerut J., Starkel P., et al. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl 14 (2008) 526-533
38. Parfitt J.R., Marotta P., Alghamdi M., Wall W., Khakhar A., Suskin N.G., et al. Recurrent hepatocellular carcinoma after transplantation: Use of a pathological score on explanted livers to predict recurrence. Liver Transpl 13 (2007) 543-551
39. Plessier A., Codes L., Consigny Y., Sommacale D., Dondero F., Cortes A., et al. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 10 Suppl. 1 (2004) S86-90
40. Marsh J.W., Finkelstein S.D., Demetris A.J., Swalsky P.A., Sasatomi E., Bandos A., et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 9 (2003) 664-671
41. Schwartz M., Dvorchik I., Roayaie S., Isabel Fiel M., Finkelstein S., Wallis Marsh J., et al. Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers. J Hepatol 49 (2008) 581-588
42. Mas V.R., Fisher R.A., Archer K.J., Yanek K.C., Williams B., Dumur C.I., et al. Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: Preliminary results. Transplantation 83 (2007) 973-981
43. Mas V.R., Maluf D.G., Archer K.J., Yanek K., Williams B., and Fisher R.A. Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. Mol Med 12 (2006) 97-104
44. Chan E.Y., Larson A.M., Fix O.K., Yeh M.M., Levy A.E., Bakthavatsalam R., et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: Implications for surveillance studies and new adjuvant therapies. Liver Transpl 14 (2008) 956-965
45. Schwartz M., Roayaie S., and Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. J Hepatol 43 (2005) 584-589
46. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530-534
47. Yokoyama I., Carr B., Saitsu H., Iwatsuki S., and Starzl T.E. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 68 (1991) 2095-2100
48. Vivarelli M., Cucchetti A., Piscaglia F., La Barba G., Bolondi L., Cavallari A., et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 11 (2005) 497-503
49. Vivarelli M., Bellusci R., Cucchetti A., Cavrini G., De Ruvo N., Aden A.A., et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?. Transplantation 74 (2002) 1746-1751
50. Zhou J., Fan J., Wang Z., Wu Z.Q., Qiu S.J., Huang X.W., et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroenterol 12 (2006) 3114-3118
51. Zimmerman M.A., Trotter J.F., Wachs M., Bak T., Campsen J., Skibba A., et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 14 (2008) 633-638
52. Kneteman N.M., Oberholzer J., Al Saghier M., Meeberg G.A., Blitz M., Ma M.M., et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10 (2004) 1301-1311
53. Toso C., Meeberg G.A., Bigam D.L., Oberholzer J., Shapiro A.M., Gutfreund K., et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects. Transplantation 83 (2007) 1162-1168
54. Xu J., Shen Z.Y., Chen X.G., Zhang Q., Bian H.J., Zhu P., et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45 (2007) 269-276
55. De la Revilla N.J., Moreno J.M., Rubio E., de Herreros T.A., Navarrete E., Lopez M.J., et al. Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas. Transplant Proc 35 (2003) 1830-1831
56. Pokorny H., Gnant M., Rasoul-Rockenschaub S., Gollackner B., Steiner B., Steger G., et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?. Am J Transplant 5 (2005) 788-794
57. Olthoff K.M., Rosove M.H., Shackleton C.R., Imagawa D.K., Farmer D.G., Northcross P., et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 221 (1995) 734-741 discussion 741-3
58. Hsieh C.B., Chou S.J., Shih M.L., Chu H.C., Chu C.H., Yu J.C., et al. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 34 (2008) 906-910
59. Roayaie S., Frischer J.S., Emre S.H., Fishbein T.M., Sheiner P.A., Sung M., et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235 (2002) 533-539
60. Bates M.J., Farkas E., Taylor D., and McFadden P.M. Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation. Ann Thorac Surg 85 (2008) 412-415
61. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
62. Dharancy S., Romano O., Lohro R., Pageaux G.P., De Ledinghen V., Hurtova M., et al. Tolerability of sorafenib in recurrent hepatocellular carcinoma after liver transplantation: a case-control study (abstract). Liver Transpl 14 S1 (2008) S216
63. Yeo W., Mok T.S., Zee B., Leung T.W., Lai P.B., Lau W.Y., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 (2005) 1532-1538
64. Chang G.J., Mahanty H.D., Quan D., Freise C.E., Ascher N.L., Roberts J.P., et al. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 6 (2000) 734-740
65. Dunkelberg J.C., Trotter J.F., Wachs M., Bak T., Kugelmas M., Steinberg T., et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 9 (2003) 463-468
66. Kovarik J.M., Kahan B.D., Kaplan B., Lorber M., Winkler M., Rouilly M., et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 69 (2001) 48-56
67. MacDonald A.S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 (2001) 271-280
68. van Hooff J.P., Squifflet J.P., Wlodarczyk Z., Vanrenterghem Y., and Paczek L. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 75 (2003) 1934-1939
69. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
70. Huang S., Shu L., Easton J., Harwood F.C., Germain G.S., Ichijo H., et al. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem 279 (2004) 36490-36496
71. Kristof A.S., Pacheco-Rodriguez G., Schremmer B., and Moss J. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther 314 (2005) 1134-1143
72. Panwalkar A., Verstovsek S., and Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100 (2004) 657-666
73. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60 (2000) 3504-3513
74. Tirado O.M., Mateo-Lozano S., and Notario V. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 24 (2005) 3348-3357
75. Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8 (2001) 249-258
76. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., and Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883-889
77. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
78. Decaens T., Luciani E., Itti E., Hulin A., Hurtova M., Laurent A., et al. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma (abstract). J Hepatol 48 S2 (2008) S13
79. Decaens T, Duvoux C. Carcinome hépatocellulaire et transplantation hépatique : rôle futur des inhibiteurs de mTOR. Gastroenterol Clin Biol 2009 (in press).
80. Dumortier J. Effet antitumoral des inhibiteurs du signal de prolifération. Gastroenterol Clin Biol 2009 (in press).